


RANGER II SFA PIVOTAL TRIAL


Prospective, Multi-Center, Randomized Controlled Trial
Ranger™ Drug-Coated Balloon vs. Uncoated Balloon (3:1). Follow-up through 5-Years

RANGER DCB DEMONSTRATED EXCEPTIONAL OUTCOMES AT 2-YEARS.

1-YEAR K-M PRIMARY PATENCY¹



2-YEAR KAPLAN-MEIER PRIMARY PATENCY ESTIMATE




*Log-rank p-value compares the entire K-M curves from time point zero to day 760 (full 2-year follow-up window)
1. RANGER II SFA RCT 1-Year Results published in JACC:CI. doi.org/10.1016/j.jcin.2021.03.021


2-YEAR KEY RESULTS

Ranger DCB delivered exceptional outcomes in complex lesions and shows significantly fewer repeat interventions compared to PTA with no difference in mortality at 2 Years.

2-YEAR K-M PRIMARY PATENCY



2-YEAR K-M FREEDOM FROM LTR AND K-M ALL-CAUSE MORTALITY



* PACSS Grade 3/4 Calcification
** Log-rank p-value compares the entire K-M curves from time point zero to day 760 (full 2-year follow-up window)
*** Log-rank p-value compares the entire K-M curves from time point zero to day 730 (full 2-year annual visit mark)

BASELINE PATIENT & LESION CHARACTERISTICS	Ranger™ DCB (n=278)	PTA (n=98)	p-value
Age (Year)	70.6	69.1	0.1887
Women	37.8%	31.6%	0.2769
Smoking History			0.0303
Current/Previous	31.3%/54.0%	45.9%/38.8%	N/A
Never/Unknown	14.4%/0.4%	15.3%/0.0%	N/A
Diabetes Mellitus	42.4%	43.9%	0.8055
Lesion Length (mm)	82.5	79.9	0.655
Moderate Calcium (PACSS Grade 3)	36.3%	52.0%	0.006
Severe Calcium (PACSS Grade 4)	11.5%	10.2%	0.724
100% (Occlusion)	18.3%	29.6%	0.019

1-YEAR PRIMARY ENDPOINT AND KEY RESULTS	Ranger™ DCB (n=278)	PTA (n=98)	p-value
Primary Safety Endpoint (Freedom from MAE)	94.1% (241/256)	83.0% (76/91)	$P_{\text{non-inferiority}} < 0.0001$
Primary Effectiveness Endpoint (Binary Primary Patency)	82.9% (194/234)	66.3% (57/86)	0.0017
CD-TLR	5.5%	16.5%	0.0011
K-M All-Cause Mortality	1.9%	2.1%	0.8794

RANGER PK SUBSTUDY¹

At one hour, 11 of 12 patients did not have measurable levels of paclitaxel in the bloodstream.

At three hours, the 12th patient did not have measurable levels of paclitaxel in their bloodstream.



1. The limit of quantification was defined as < 1 ng/mL. RANGER II SFA PK Substudy. RANGER II SFA RCT 12-Month Results published in JACC:CI. doi.org/10.1016/j.jcin.2021.03.021

**Boston
Scientific**

Advancing science for life™

Peripheral Interventions

bostonscientific.eu

© 2021 Boston Scientific Corporation or its affiliates. All rights reserved.

PI-961904-AB

RANGER DRUG COATED BALLOON

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labelling supplied with each device. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material is not intended for use in France.

Ranger is a registered or unregistered trademark of Boston Scientific Corporation or its affiliates. All other trademarks are property of their respective owners.